company background image
NOVO B logo

Novo Nordisk CPSE:NOVO B Stock Report

Last Price

DKK 615.40

Market Cap

DKK 2.8t

7D

2.6%

1Y

-25.9%

Updated

10 Feb, 2025

Data

Company Financials +

Novo Nordisk A/S

CPSE:NOVO B Stock Report

Market Cap: DKK 2.8t

NOVO B Stock Overview

Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More details

NOVO B fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends4/6

Rewards

Trading at 59.4% below our estimate of its fair value

Earnings are forecast to grow 12.66% per year

Earnings grew by 20.7% over the past year

Risk Analysis

High level of non-cash earnings

Unstable dividend track record

Volatile share price over the past 3 months compared to the Danish market

Has a high level of debt


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 24 Analysts

R&D And Acquisitions Will Broaden Portfolio Across Multiple Diseases

Key Takeaways Strategic market expansion and supply chain investments are set to boost Novo Nordisk's revenue growth through increased production and broader geographical reach. Diversification through R&D and strategic acquisitions will enhance portfolio breadth, tapping new revenue streams and improving operational efficiencies.
View narrative
DKK 824.65
FV
25.4% undervalued intrinsic discount
16.99%
Revenue growth p.a.
2users have liked this narrative
0users have commented on this narrative
117users have followed this narrative
12 days ago author updated this narrative

My Notes

Capture your thoughts, links and company narrative

Novo Nordisk A/S Competitors

H. Lundbeck

CPSE:HLUN B

DKK 40.9b

ALK-Abelló

CPSE:ALK B

DKK 35.4b

Johnson & Johnson

NYSE:JNJ

US$368.7b

Eli Lilly

NYSE:LLY

US$790.9b

Price History & Performance

Summary of share price highs, lows and changes for Novo Nordisk
Historical stock prices
Current Share PriceDKK 615.40
52 Week HighDKK 1,033.20
52 Week LowDKK 526.00
Beta0.19
1 Month Change-2.67%
3 Month Change-17.83%
1 Year Change-25.91%
3 Year Change91.39%
5 Year Change180.62%
Change since IPO22,734.89%

Recent News & Updates

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Recent updates

Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

Feb 10
Novo Nordisk's (CPH:NOVO B) Upcoming Dividend Will Be Larger Than Last Year's

The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Feb 07
The Novo Nordisk A/S (CPH:NOVO B) Full-Year Results Are Out And Analysts Have Published New Forecasts

Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Jan 09
Novo Nordisk A/S (CPH:NOVO B) Not Flying Under The Radar

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Dec 23
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Nov 13
Solid Earnings May Not Tell The Whole Story For Novo Nordisk (CPH:NOVO B)

Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 09
Novo Nordisk A/S (CPH:NOVO B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Nov 01
Is Novo Nordisk A/S (CPH:NOVO B) Trading At A 31% Discount?

Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Oct 09
Novo Nordisk A/S' (CPH:NOVO B) P/E Still Appears To Be Reasonable

Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Jul 27
Is Novo Nordisk (CPH:NOVO B) Using Too Much Debt?

Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

Jul 05
Should You Be Adding Novo Nordisk (CPH:NOVO B) To Your Watchlist Today?

A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Jun 09
A Look At The Fair Value Of Novo Nordisk A/S (CPH:NOVO B)

Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

May 09
Novo Nordisk's (CPH:NOVO B) Promising Earnings May Rest On Soft Foundations

Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

May 04
Results: Novo Nordisk A/S Beat Earnings Expectations And Analysts Now Have New Forecasts

The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Apr 28
The Price Is Right For Novo Nordisk A/S (CPH:NOVO B)

Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Apr 14
Does Novo Nordisk (CPH:NOVO B) Have A Healthy Balance Sheet?

Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Mar 18
Do Novo Nordisk's (CPH:NOVO B) Earnings Warrant Your Attention?

Shareholder Returns

NOVO BDK PharmaceuticalsDK Market
7D2.6%3.4%2.7%
1Y-25.9%-23.6%-14.6%

Return vs Industry: NOVO B underperformed the Danish Pharmaceuticals industry which returned -23.6% over the past year.

Return vs Market: NOVO B underperformed the Danish Market which returned -14.6% over the past year.

Price Volatility

Is NOVO B's price volatile compared to industry and market?
NOVO B volatility
NOVO B Average Weekly Movement8.3%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement4.5%
10% most volatile stocks in DK Market10.6%
10% least volatile stocks in DK Market2.9%

Stable Share Price: NOVO B's share price has been volatile over the past 3 months compared to the Danish market.

Volatility Over Time: NOVO B's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

FoundedEmployeesCEOWebsite
192376,826Lars Jorgensenwww.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NOVO B fundamental statistics
Market capDKK 2.79t
Earnings (TTM)DKK 100.99b
Revenue (TTM)DKK 290.40b

27.1x

P/E Ratio

9.4x

P/S Ratio

Is NOVO B overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVO B income statement (TTM)
RevenueDKK 290.40b
Cost of RevenueDKK 43.56b
Gross ProfitDKK 246.84b
Other ExpensesDKK 145.86b
EarningsDKK 100.99b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 07, 2025

Earnings per share (EPS)22.75
Gross Margin85.00%
Net Profit Margin34.78%
Debt/Equity Ratio66.9%

How did NOVO B perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

50%

Payout Ratio

Does NOVO B pay a reliable dividends?

See NOVO B dividend history and benchmarks
When do you need to buy NOVO B by to receive an upcoming dividend?
Novo Nordisk dividend dates
Ex Dividend DateMar 28 2025
Dividend Pay DateApr 01 2025
Days until Ex dividend45 days
Days until Dividend pay date49 days

Does NOVO B pay a reliable dividends?

See NOVO B dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/10 18:26
End of Day Share Price 2025/02/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 67 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research